Cargando…
Receptor Activator of Nuclear Factor Kappa B (RANK) and Clinicopathological Variables in Endometrial Cancer: A Study at Protein and Gene Level
The system integrated by the receptor activator of nuclear factor kappa B (RANK) and its ligand, RANKL, modulates the role of hormones in the genesis and progression of breast tumors. We investigated whether the expression of RANK was related with clinicopathological features of primary endometrial...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073139/ https://www.ncbi.nlm.nih.gov/pubmed/29932437 http://dx.doi.org/10.3390/ijms19071848 |
_version_ | 1783344125449338880 |
---|---|
author | Gómez, Raúl Castro, Ana Martínez, Jessica Rodríguez-García, Víctor Burgués, Octavio Tarín, Juan J. Cano, Antonio |
author_facet | Gómez, Raúl Castro, Ana Martínez, Jessica Rodríguez-García, Víctor Burgués, Octavio Tarín, Juan J. Cano, Antonio |
author_sort | Gómez, Raúl |
collection | PubMed |
description | The system integrated by the receptor activator of nuclear factor kappa B (RANK) and its ligand, RANKL, modulates the role of hormones in the genesis and progression of breast tumors. We investigated whether the expression of RANK was related with clinicopathological features of primary endometrial tumors. Immunohistochemistry was used in an endometrial cancer tissue array containing samples from 36 tumors. The amount of RANK mRNA was examined in a tissue scan cDNA array containing cDNA from 40 tumors. Normal endometrium was examined for comparison. Immunohistochemical analyses showed that RANK expression was higher in malignant than in normal endometrium (p < 0.05). RANK expression was related to histological grade (Pearson correlation index = 0.484, p < 0.001), but not to tumor stage or to age of the women. The gene expression was similar in malignant and normal endometrium. The study of RANK isoforms confirmed that the overall relative abundance of the three clearly identified transcripts was similar in normal and pathological endometrium. RANK protein expression increased from normal to malignant endometrium, and the expression level was related with tumor grade but not with stage or the age of subjects in endometrial cancer. In contrast, similar comparisons showed no change in RANK gene expression. |
format | Online Article Text |
id | pubmed-6073139 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-60731392018-08-13 Receptor Activator of Nuclear Factor Kappa B (RANK) and Clinicopathological Variables in Endometrial Cancer: A Study at Protein and Gene Level Gómez, Raúl Castro, Ana Martínez, Jessica Rodríguez-García, Víctor Burgués, Octavio Tarín, Juan J. Cano, Antonio Int J Mol Sci Article The system integrated by the receptor activator of nuclear factor kappa B (RANK) and its ligand, RANKL, modulates the role of hormones in the genesis and progression of breast tumors. We investigated whether the expression of RANK was related with clinicopathological features of primary endometrial tumors. Immunohistochemistry was used in an endometrial cancer tissue array containing samples from 36 tumors. The amount of RANK mRNA was examined in a tissue scan cDNA array containing cDNA from 40 tumors. Normal endometrium was examined for comparison. Immunohistochemical analyses showed that RANK expression was higher in malignant than in normal endometrium (p < 0.05). RANK expression was related to histological grade (Pearson correlation index = 0.484, p < 0.001), but not to tumor stage or to age of the women. The gene expression was similar in malignant and normal endometrium. The study of RANK isoforms confirmed that the overall relative abundance of the three clearly identified transcripts was similar in normal and pathological endometrium. RANK protein expression increased from normal to malignant endometrium, and the expression level was related with tumor grade but not with stage or the age of subjects in endometrial cancer. In contrast, similar comparisons showed no change in RANK gene expression. MDPI 2018-06-22 /pmc/articles/PMC6073139/ /pubmed/29932437 http://dx.doi.org/10.3390/ijms19071848 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gómez, Raúl Castro, Ana Martínez, Jessica Rodríguez-García, Víctor Burgués, Octavio Tarín, Juan J. Cano, Antonio Receptor Activator of Nuclear Factor Kappa B (RANK) and Clinicopathological Variables in Endometrial Cancer: A Study at Protein and Gene Level |
title | Receptor Activator of Nuclear Factor Kappa B (RANK) and Clinicopathological Variables in Endometrial Cancer: A Study at Protein and Gene Level |
title_full | Receptor Activator of Nuclear Factor Kappa B (RANK) and Clinicopathological Variables in Endometrial Cancer: A Study at Protein and Gene Level |
title_fullStr | Receptor Activator of Nuclear Factor Kappa B (RANK) and Clinicopathological Variables in Endometrial Cancer: A Study at Protein and Gene Level |
title_full_unstemmed | Receptor Activator of Nuclear Factor Kappa B (RANK) and Clinicopathological Variables in Endometrial Cancer: A Study at Protein and Gene Level |
title_short | Receptor Activator of Nuclear Factor Kappa B (RANK) and Clinicopathological Variables in Endometrial Cancer: A Study at Protein and Gene Level |
title_sort | receptor activator of nuclear factor kappa b (rank) and clinicopathological variables in endometrial cancer: a study at protein and gene level |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073139/ https://www.ncbi.nlm.nih.gov/pubmed/29932437 http://dx.doi.org/10.3390/ijms19071848 |
work_keys_str_mv | AT gomezraul receptoractivatorofnuclearfactorkappabrankandclinicopathologicalvariablesinendometrialcancerastudyatproteinandgenelevel AT castroana receptoractivatorofnuclearfactorkappabrankandclinicopathologicalvariablesinendometrialcancerastudyatproteinandgenelevel AT martinezjessica receptoractivatorofnuclearfactorkappabrankandclinicopathologicalvariablesinendometrialcancerastudyatproteinandgenelevel AT rodriguezgarciavictor receptoractivatorofnuclearfactorkappabrankandclinicopathologicalvariablesinendometrialcancerastudyatproteinandgenelevel AT burguesoctavio receptoractivatorofnuclearfactorkappabrankandclinicopathologicalvariablesinendometrialcancerastudyatproteinandgenelevel AT tarinjuanj receptoractivatorofnuclearfactorkappabrankandclinicopathologicalvariablesinendometrialcancerastudyatproteinandgenelevel AT canoantonio receptoractivatorofnuclearfactorkappabrankandclinicopathologicalvariablesinendometrialcancerastudyatproteinandgenelevel |